GALT · Galectin Therapeutics Inc.

Galectin Therapeutics reported significantly improved Q1 2026 financial results, with net loss narrowing to $5.1 million or ($0.08) per share from $9.6 million or ($0.15) per share in Q1 2025, primarily due to a sharp decline in research and development expenses from $6.5 million to $2.2 million, attributed to the timing of NAVIGATE clinical trial expenditures now largely complete. General and administrative expenses rose modestly to $1.8 million from $1.4 million, driven by higher non-cash stock-based compensation. The balance sheet remains viable with $14.1 million in cash and equivalents as of March 31, 2026, supplemented by $10 million available under a line of credit from the chairman, supporting operations through May 2027 without immediate dilution risk. CEO Joel Lewis highlighted ongoing progress in the belapectin program, with additional NAVIGATE Phase 2b/3 analyses demonstrating statistically significant reductions in liver stiffness measurements at multiple timepoints in the 2 mg/kg arm versus placebo, and a 11.7% versus 23.9% rate of clinically meaningful worsening (p=0.03), signaling potential to slow fibrosis progression in high-risk MASH cirrhosis patients. These findings bolster belapectin's profile ahead of key catalysts: oral and poster presentations at EASL Congress on May 28-30, 2026, focusing on fibrogenesis biomarkers and portal hypertension risk reduction, plus an in-person FDA Type-C meeting this quarter to align on next steps. Corporate governance strengthened with Dr. Henry Brem's January board appointment. While no formal guidance was issued, management emphasized partner engagement and data-driven path forward, underscoring a pivotal phase for this galectin-3 inhibitor with Fast Track designation.